Production Linked Incentive (PLI) Scheme For KSM/Drug Intermediates and API
The Department of Pharmaceuticals has accorded approvals under Production Linked Incentive (PLI) Scheme for Promotion of Domestic Manufacturing of critical Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs).
- The Department of Pharmaceuticals has launched this scheme with an objective to attain self-reliance and reduce import dependence in critical Bulk Drugs – Key Starting Materials (KSMs)/ Drug Intermediates and Active Pharmaceutical Ingredients (APIs).
- This will be achieved by promotion of their domestic manufacturing by setting up greenfield plants with minimum domestic value addition in four different Target Segments with a total outlay of Rs.6,940 cr. for the period 2020-21 to 2029-30.
- Setting up these plants will make the country self-reliant to a large extent in respect of these Bulk drugs.
- The disbursal of production linked incentive by the Government over the six years period would be up to a maximum of about Rs.6,000 cr.
